Dragomabin is a lipopeptide isolated from the marine cyanobacteria Lyngbya majuscula.

[1] It has in vitro antimalarial activity.

[1] In 2018, a laboratory synthesis of dragomabin was reported.

[2] The synthesis identified a misassignment of the configuration of the stereogenic center on the alkyne-bearing fragment and it was revised from (S) to (R).

This article about an organic compound is a stub.